Cresco Labs Inc. CRLBF

What this company does

Cresco is licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, its national dispensary brand, and through wholesaling to third-party retail stores. Its portfolio includes over 500 unique products and over 6,600 unique stock-keeping-units, sold in nearly 1,400 dispensaries across the country. Cresco operates 73 dispensaries, as of March 5, 2026. Following the sale of its Sonoma's Finest cultivation facility and exit of the California market in the fourth quarter of 2025, the company realigned its operations into two operating segments, consolidated wholesale and consolidated retail. It operates or plans to operate ten cultivation facilities, totaling approximately 0.4 million square feet, across seven states: Illinois, Pennsylvania, Ohio, Kentucky, Massachusetts, Michigan and Florida. As of December 31, 2025, Cresco had approximately 2,900 employees across its operating jurisdictions, primarily employed in its cultivation, manufacturing and processing operations. The company began trading on the Canadian Securities Exchange under the ticker symbol "CL" on December 3, 2018.

Written from the business description in Cresco Labs Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 6 March 2026. Every sentence was checked against that document before publication.